SCL Science and KAIST Sign MOU for Collaboration on Medical Data-Based Bio Platform Business

SCL Science, an affiliate of the SCL Group, is taking a full-scale step toward commercialization using medical data in collaboration with KAIST.

Baek Se-yeon, CEO of SCL Science (left), Choi Jung-gyun, KAIST professor, Lee Kyung-ryul, chairman of SCL Group, and Kim Pil-nam, KAIST professor, at the signing ceremony. Photo by SCL Science

SCL Science and KAIST announced on the 13th that they held an opening ceremony for the Translational Medicine Research Institute and signed a strategic business agreement (MOU).

The signing ceremony took place at the SCL Group headquarters located in Yongin, Gyeonggi Province. Attendees included Lee Kyung-ryul, Chairman of SCL Group; Baek Se-yeon, CEO of SCL Science; Professor Choi Jung-gyun of KAIST; and Professor Kim Pil-nam of KAIST.

Through this business agreement, SCL Science plans to combine the screening and specimen data resources owned by SCL Group with KAIST's advanced data analysis capabilities to establish various collaborative systems. This will accelerate the commercialization of data-driven bio-platforms and digital healthcare, which SCL Science is expanding investment in as a new growth engine.

An SCL Science official stated, "SCL Group has secured a vast amount of medical data through its long-standing screening and specimen testing business," adding, "Based on the 'Discovery of Korean-specific genomic variations and chromosomal variation testing' developed by SCL Group, we are preparing to develop disease risk prediction algorithms using bio big data and to discover new drug candidates."

They continued, "With the signing of this business agreement, we will accelerate the commercialization of various bio-platforms such as medical data-based bioinformatics and create new value in the digital healthcare sector."

In September, SCL Science appointed Professor Choi Jung-gyun of KAIST's Department of Bio and Brain Engineering as an outside director to accelerate its digital and bio-platform business. Professor Choi is a big data expert who gained attention this year for participating in the construction of the world's largest cancer tissue single-cell and spatial transcriptome database.

Meanwhile, SCL Group is a total healthcare group that owns healthcare affiliates including SCL, Korea's first specialized testing institution established in 1983; SCL Healthcare, which has a global-level clinical trial specimen analysis institution; SCL Science (a KOSDAQ-listed company) focusing on digital and bio-platforms; Hanaro Medical Foundation, a screening specialist institution; SCL Holdings; Bio Food Lab; and Ahels.

This content was produced with the assistance of AI translation services.